Results 171 to 180 of about 6,899,160 (286)

Effective therapeutic targeting of CTNNB1‐mutant hepatoblastoma with WNTinib

Molecular Oncology, EarlyView.
WNTinib, a Wnt/CTNNB1 inhibitor, was tested in hepatoblastoma (HB) experimental models. It delayed tumor growth and improved survival in CTNNB1‐mutant in vivo models. In organoids, WNTinib outperformed cisplatin and showed enhanced efficacy in combination therapy, supporting its potential as a targeted treatment for CTNNB1‐mutated HB.
Ugne Balaseviciute, Júlia Huguet‐Pradell, Jordi Abril‐Fornaguera, Albert Gris‐Oliver, Alex Rialdi, Elisa Fernández‐Martínez, Carla Montironi, Vanessa Del Pozo, Peter Houghton, Laura Zanatto, Agavni Mesropian, Ieva Keraite, Swan Thung, Carolina Armengol, Pau Sancho‐Bru, Ernesto Guccione, Roser Pinyol, Josep M. Llovet   +17 more
wiley   +1 more source

Improving the quality of child and youth mental health care through an implementation science lens. [PDF]

Front Health Serv
Dumke L, Hall J, Jung J, Sibilio R, Beinerte K, Beļikova R, Mavreas V, Stylianidis S, Azzopardi-Muscat N, Lazeri L, Oldenburg B, Breda J.   +11 more
europepmc   +1 more source

Exploiting metabolic adaptations to overcome dabrafenib treatment resistance in melanoma cells

Molecular Oncology, EarlyView.
We show that dabrafenib‐resistant melanoma cells undergo mitochondrial remodeling, leading to elevated respiration and ROS production balanced by stronger antioxidant defenses. This altered redox state promotes survival despite mitochondrial damage but renders resistant cells highly vulnerable to ROS‐inducing compounds such as PEITC, highlighting redox
Silvia Eller, Susanne Ebner, Carmen Haselrieder, Julia K. Günther, Astrid Drasche, Sophie Strich, Chiara Volani, Andrea Medici, Aleksandar Nikolajevic, Alex Deltedesco, Johannes E. Sigmund, Michael J. Blumer, Martin Hermann, Johanna Vanacker, Gerald Brandacher, Eduard Stefan, Omar Torres‐Quesada, Jakob Troppmair   +17 more
wiley   +1 more source

From data to decisions: Toward a Biodiversity Monitoring Standards Framework. [PDF]

Proc Natl Acad Sci U S A
Gonzalez A, August T, Bailey S, Bobiwash K, Boersch-Supan PH, Burgess ND, Daru BH, Elphick CS, Freckleton RP, Frick WF, Hughes AC, Isaac NJB, Jones JPG, Lambertini M, Mac Aodha O, Madhavapeddy A, Milner-Gulland EJ, Purvis A, Salafsky N, Sutherland WJ, Tanshi I, Vijay V, Woodard SH, Williams DR.   +23 more
europepmc   +1 more source

Monitoring of circulating tumor DNA allows early detection of disease relapse in patients with operable breast cancer

Molecular Oncology, EarlyView.
Monitoring circulating tumor DNA (ctDNA) in patients with operable breast cancer can reveal disease relapse earlier than radiology in a subset of patients. The failure to detect ctDNA in some patients with recurrent disease suggests that ctDNA could serve as a supplement to other monitoring approaches.
Kristin Løge Aanestad, Marie Austdal, Oddmund Nordgård, Gunnar Mellgren, Satu Oltedal, Marie L. Austbø, Ylva H. Vignes, Thomas Helland, Kristin Jonsdottir, Tone H. Lende, Emilius A. M. Janssen, Bjørnar Gilje, Kjersti Tjensvoll, PBCB study group, Gunnar Mellgren, Tone Hoel Lende, Anette Heie, Kristin Viste, Anita Røyneberg Alvheim, Emiel AM Janssen, Kristin Jonsdottir, Ann Cathrine Kroksveen, Thomas Helland, Einar Gudlaugsson, Oddmund Nordgård, Satu Oltedal, Kristin Løge Aanestad, Jan Terje Kvaløy, Kirsten Lode, Kari Britt Hagen, Marie Austdal, Ylva H. Vignes, Siri Tungland Sola, Nina Egeland Amundsen, Finn Magnus Eliassen, Emeritus Ernst A Lien   +35 more
wiley   +1 more source

Lack of harmonisation in immunological data: challenges in synthesising data during the COVID-19 pandemic. [PDF]

EBioMedicine
Shaver N, Colijn C, Heffernan J, Asamoah GD, Piggott T, Cooper C, Bagheri S, Crawley AM, Kagina BM, Bowdish DME, Langlois MA, Little J.   +11 more
europepmc   +1 more source

Cafcass national standards [PDF]

, 2007

core  

LINC01116, a hypoxia‐lncRNA marker of pathological lymphangiogenesis and poor prognosis in lung adenocarcinoma

Molecular Oncology, EarlyView.
The LINC01116 long noncoding RNA is induced by hypoxia and associated with poor prognosis and high recurrence rates in two cohorts of lung adenocarcinoma patients. Here, we demonstrate that besides its expression in cancer cells, LINC01116 is markedly expressed in lymphatic endothelial cells of the tumor stroma in which it participates in hypoxia ...
Marine Gautier‐Isola, Rafael Lopes Goncalves, Marin Truchi, Caroline Lacoux, Célia Scribe, Hugo Cadis, Laetitia Guardini, Sophie Bekisz, Marius Ilié, Paul Hofman, Georges Vassaux, Bernard Mari, Roger Rezzonico   +12 more
wiley   +1 more source

Surgical Trainee Familiarity and Knowledge of the Commission on Cancer (CoC) Operative Standards: A National Survey Study. [PDF]

J Am Coll Surg
Baskin AS, Funk EC, Sample JW, Francescatti AB, Pastore BM, Lee C, Boffa DJ, Dossett LA, Weigel RJ, Hieken TJ, Teshome M, Wang TS, Vreeland TJ, Zaveri S.   +13 more
europepmc   +1 more source

Falling credit standards? [PDF]

, 2001
Garratt, D, Pannell, B
core